Q3 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Jagsonpal Pharmaceuticals Ltd (BOM:507789) reported a 6% year-on-year growth in revenue for the nine-month period, with a 13% improvement in the bottom line.
- The company achieved an EBITDA margin of 22.7% for the quarter, reflecting strong operational resilience.
- The leadership team has been strengthened with the appointment of a new CEO and CFO, contributing to strategic growth initiatives.
- The acquisition of Yash Pharma has been successful, contributing positively to growth and expanding the company's therapeutic areas.
- The company has a strong cash position, with a free cash balance of INR176 crores, reflecting disciplined operational management.
- The quarterly performance was described as 'flattish,' falling below both company and market expectations.
- The company's RPM growth was slower than the broader Indian pharmaceutical market, at 3% to 3.5% compared to the industry's 8%.
- There were temporary disruptions due to GST changes and internal strategic realignments, impacting short-term growth.
- The company faces challenges in improving field force productivity, which has been a persistent issue.
- Despite a strong cash position, the company has not yet identified suitable M&A opportunities to effectively utilize its cash reserves.
Ladies and gentlemen, good day and welcome to the Q3 and nine months FY26 earnings conference call for Jagsonpal Pharmaceuticals Limited. (Operator Instructions) I now hand the conference over to Miss Soumya Chhajed from Go India Advisors. Thank you and over to you, ma'am.
Good evening, everyone and welcome to Q3 and nine months FY26 earnings on call of Jagsonpal Pharmaceuticals Ltd. We have on call with us Manish Gupta, the Managing Director, Amrut Medhekar , the Chief Operating Officer, and Nirav Vora, the Chief Financial Officer.
We must remind you that discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risks pertaining to the business. I now request the management to take us to the same and provide some more insight on the quarter gone by. For that, we'll open the floor to Q&A.
Yes, thank you,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
